Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the U.S. Department of Veteran’s Affairs. Agency clinicians instead approved the depression spray’s use on a limited basis, requiring patients to try other options first.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,